1 / 47

A Predictive Assay for Success Rates of Islet Transplantation to Treat Type-1 Diabetes

This study aims to engineer an assay to enhance islet transplantation success in type-1 diabetics, aiding patient-donor matching and in vitro monitoring. The assay measures TNFα production to correlate with failed transplants. Methods involve modifying the ELISPOT assay and testing cell-to-cell ratios. Findings show a significant correlation between heightened TNFα production and failed transplantation. Benefits include personalized immunosuppression, reducing medication use. Future research includes testing more patient samples at different transplantation stages.

iden
Download Presentation

A Predictive Assay for Success Rates of Islet Transplantation to Treat Type-1 Diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Predictive Assay for Success Rates of Islet Transplantation to Treat Type-1 Diabetes Tracy Fuad 2007

  2. Diabetes Institute of Immunology and Transplantation

  3. Objective • Engineer an assay to improve success rates of islet transplantation in type-1 diabetics • As a tool to match patients to donors • As an in vitro monitoring tool

  4. Type-1 Diabetes • An auto-immune disease • Characterized by loss of pancreatic islet cell function

  5. Type-1 Diabetes Islet Cells • An auto-immune disease • Characterized by loss of pancreatic islet cell function http://www.diabetesresearch.org

  6. Islet Transplantation http://www.rsna.org/rsna/media/

  7. Immune-Mediated Graft Rejection • Patient’s immune system recognizes islets as foreign • Immune system attacks and destroys transplanted tissues

  8. HLA-Matching • Human leukocyte-antigen typing (HLA-typing) matches tissues to minimize the immune response in a transplant • Immune response can be also be measured by cytokine production

  9. ELISPOT Assay • Enzyme-linked immunospot assay • Quantifies the cytokine production of lymphocytes (white blood cells) • TNF is an inflammatory cytokine that is produced during transplantation and rejection

  10. Goals • Optimize ELISPOT assay to test TNF production in donor-stimulated patient cells • Use the modified ELISPOT protocol to look for a correlation between failed transplants and elevated TNF production

  11. Previous Studies • Studies by Augustine et al. and Bellisola et al. have correlated heightened IFN production in an ELISPOT assay to increased rates of renal transplant rejection

  12. Hypothesis • Because IFN is an inflammatory cytokine often produced in conjunction with TNF, I hypothesized that heightened TNF production would correlate with failed islet transplants

  13. Methods: ELISPOT Assay • Uses a 96-well plate with nitrocellulose membranes • Quantifies cytokines by capturing them locally and visualizing each cytokine

  14. ELISPOT well

  15. Capture antibody

  16. Capture antibody

  17. Blocked with protein serum

  18. Leukocytes or splenocytes are added

  19. Cytokines Released

  20. Detection Antibody

  21. Detection Antibody

  22. Strepdavidan-HRP, a colored substrate  

  23. Precipitation reaction

  24. Reading the ELISPOT Plate  http://www.biosciencetechnology.com/images

  25. Reading the ELISPOT Plate www.elispot.com/index.html?elispot_reader/software.html

  26. ELISPOT Modification • Increased the protein concentration of blocking buffers • Reduced the number of cells per well • Decreased secondary detection antibody incubation time • Added more washes between steps

  27. Cell-to-Cell ELISPOT • Used to find the optimal donor-to-patient cell-to-cell ratio

  28. TNF Allo-Titration ELISPOT

  29. TNF Allo-Titration ELISPOT

  30. TNF Allo-Titration ELISPOT

  31. TNF Allo-Titration ELISPOT

  32. Donor-to-Patient Induced Immune Response • Islet transplant patient was selected • First transplant failed • Second transplant was successful • Patient cells stimulated with cells from each donor

  33. Donor-to-Patient Induced Immune Response • Modified ELISPOT protocol used with the following plate map:

  34. TNF Clinical Patient ELISPOT

  35. TNF Clinical Patient ELISPOT  Positive Controls 

  36. TNF Clinical Patient ELISPOT Positive Controls 

  37. TNF Clinical Patient ELISPOT  Negative Controls  

  38. TNF Clinical Patient ELISPOT  Failed Transplant  Successful transplant

  39. Failed Transplant

  40. Successful Transplant

  41. p=0.0000892

  42. Conclusion • TNF ELISPOT assay is an effective means to measure immune response in transplantation patients • Heightened TNF production has a statistically significant correlation to failed transplantation

  43. Applications • A tool to match patients to donors • An in vitro monitoring assay • Identify immunosuppression needs of individual patients • Reduce the use of immunosuppresant medications

  44. Future Studies • Test samples from additional islet transplant patients • Test patient samples from different points in transplantation timeline

  45. Acknowledgements • The University of Minnesota and Dr. Bernard Hering • Dr. Pratima Pakala, Kelly Hire, Adam Nettles, and Olivia Thai • Ms. Fruen and the Science Research Class

  46. A Predictive Assay for Success Rates of Islet Transplantation to Treat Type-1 Diabetes Tracy Fuad 2007

More Related